Loading...
Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia.
Sundarasetty, Bala Sai Singh, Vijay Kumar Salguero, Gustavo Rickmann, Mareike Macke, Laura Borchers, Sylvia Figueiredo, Constanca Schambach, Axel Gullberg, Urban
Sundarasetty, Bala Sai
Singh, Vijay Kumar
Salguero, Gustavo
Rickmann, Mareike
Macke, Laura
Borchers, Sylvia
Figueiredo, Constanca
Schambach, Axel
Gullberg, Urban
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2013-02
Submitted date
Files
Loading...
allowed oublishers' PDF
Adobe PDF, 1.04 MB
Other Titles
Abstract
Wilms' tumor 1 antigen (WT1) is overexpressed in acute myeloid leukemia (AML), a high-risk neoplasm warranting development of novel immunotherapeutic approaches. Unfortunately, clinical immunotherapeutic use of WT1 peptides against AML has been inconclusive. With the rationale of stimulating multiantigenic responses against WT1, we genetically programmed long-lasting dendritic cells capable of producing and processing endogenous WT1 epitopes. A tricistronic lentiviral vector co-expressing a truncated form of WT1 (lacking the DNA-binding domain), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukin-4 (IL-4) was used to transduce human monocytes ex vivo. Overnight transduction induced self-differentiation of monocytes into immunophenotypically stable "SmartDC/tWT1" (GM-CSF(+), IL-4(+), tWT1(+), IL-6(+), IL-8(+), TNF-α(+), MCP-1(+), HLA-DR(+), CD86(+), CCR2(+), CCR5(+)) that were viable for 3 weeks in vitro. SmartDC/tWT1 were produced with peripheral blood mononuclear cells (PBMC) obtained from an FLT3-ITD(+) AML patient and surplus material from a donor lymphocyte infusion (DLI) and used to expand CD8(+) T cells in vitro. Expanded cytotoxic T lymphocytes (CTLs) showed antigen-specific reactivity against WT1 and against WT1(+) leukemia cells. SmartDC/tWT1 injected s.c. into Nod.Rag1(-/-).IL2rγc(-/-) mice were viable in vivo for more than three weeks. Migration of human T cells (huCTLs) to the immunization site was demonstrated following adoptive transfer of huCTLs into mice immunized with SmartDC/tWT1. Furthermore, SmartDC/tWT1 immunization plus adoptive transfer of T cells reactive against WT1 into mice resulted in growth arrest of a WT1(+) tumor. Gene array analyses of SmartDC/tWT1 demonstrated upregulation of several genes related to innate immunity. Thus, SmartDC/tWT1 can be produced in a single day of ex vivo gene transfer, are highly viable in vivo, and have great potential for use as immunotherapy against malignant transformation overexpressing WT1.
Citation
Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia. 2013, 24 (2):220-37 Hum. Gene Ther.
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
1557-7422
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Archived with thanks to Human gene therapy